UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 31, 2001
OXIGENE, INC.
-------------
(Exact name of registrant as specified in its charter)
Delaware 0-21990 13-3679168
--------------- ------------- --------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
321 Arsenal Street
------------------
Watertown, Massachusetts 02472
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 673-7800
-1-
Item 5. Other Events and Regulation FD Disclosure.
On October 31, 2001, the Registrant issued a press release, a copy of which is
attached hereto as Exhibit 99.1, announcing that it has completed the Phase I
U.S. clinical trial of its novel anti-tumor vascular targeting agent,
Combretastatin A4 Prodrug (CA4P). The trial generated statistically significant
findings demonstrating CA4P's ability to successfully reduce blood flow that
feeds malignant tumors. CA4P is the first vascular targeting drug to be tested
in a human trial in the United States.
Item 7. Financial Statements and Exhibits.
(c) The following exhibits are filed with this report:
Exhibit Number Description
-------------- -----------
99.1 Press release of Registrant dated October 31, 2001.
99.2 Transcript of conference call conducted by Registrant on
November 1, 2001.
Item 9. Regulation FD Disclosure.
On November 1, 2001, the Registrant held a conference call (the "Conference
Call") to discuss and comment on the completion of the Phase I U.S. clinical
trial of its novel anti-tumor vascular targeting agent, Combretastatin A4
Prodrug (CA4P). A transcript of the Conference Call is attached hereto as
Exhibit 99.2.
-2-
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OXIGENE, INC.
-------------
(Registrant)
Date: November 5, 2001 By: /s/ Frederick Driscoll
-----------------------
Name: Frederick Driscoll
Title: President of Operations and Finance
-3-
EXHIBIT INDEX
-------------
Exhibit Number Description
-------------- -----------
99.1 Press release of Registrant dated October 31, 2001.
99.2 Transcript of conference call conducted by Registrant on
November 1, 2001.
-4-